PreprintAll rights reservedbioRxiv
THERAPY RESISTANCE IN MELANOMA DRIVES CILIOGENESIS AND GLUTAMINE/ASPARTATE METABOLISM DEPENDENCY
- 1University of Padua
Related
- Targeting SLC1A5-mediated glutamine metabolism overcomes PARP inhibitor resistance in ovarian cancer.
- The glutamine-aspartate metabolic tradeoff between fast growth and metabolic flexibility
- Glutamine Metabolism in Cardiac Hypertrophy
- Aberrant Accumulation of Cyclin D1 Rewires Glutamine Metabolism and Generates a Metabolic Vulnerability in Squamous Cell Carcinoma
- ARHGAP40 suppresses clear cell renal cell carcinoma progression and is associated with altered glutamine-related metabolism and redox balance.
BibTeX
@misc{lugato2026therapy,
title = {{THERAPY RESISTANCE IN MELANOMA DRIVES CILIOGENESIS AND GLUTAMINE/ASPARTATE METABOLISM DEPENDENCY}},
author = {P. Lugato and R. Castro and C. Thomas and S. Pedretti and R. Oberkersch and N. Mitro and M. M. Santoro},
howpublished = {bioRxiv},
year = {2026},
month = oct,
doi = {10.64898/2026.10.13.758838},
url = {https://www.biorxiv.org/content/10.64898/2026.10.13.758838v1},
}
RIS
TY - UNPB
TI - THERAPY RESISTANCE IN MELANOMA DRIVES CILIOGENESIS AND GLUTAMINE/ASPARTATE METABOLISM DEPENDENCY
AU - P. Lugato
AU - R. Castro
AU - C. Thomas
AU - S. Pedretti
AU - R. Oberkersch
AU - N. Mitro
AU - M. M. Santoro
PY - 2026
DA - 2026/10/13
PB - bioRxiv
DO - 10.64898/2026.10.13.758838
UR - https://www.biorxiv.org/content/10.64898/2026.10.13.758838v1
ER -